Delving into the Latest Updates on Unoprostone Isopropyl with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

13,14-dihydro-15-keto-20-ethyl PGF2α, Isopropyl unoprostone, Isopropyl unoprostone (JAN)

+ [5]

Target

PTGFR

Action

agonists

Mechanism

PTGFR agonists(Prostanoid FP receptor agonists)

Therapeutic Areas

Eye Diseases

Active Indication

GlaucomaOcular Hypertension

Inactive Indication

Originator Organization

R-Tech Ueno, Ltd.

Active Organization

Novartis Pharma KKNitto Pharmaceutical Industries Ltd.

Inactive Organization

R-Tech Ueno, Ltd.Sucampo Pharma Americas LLC

License Organization

R-Tech Ueno, Ltd.Sucampo GmbH

Drug Highest PhaseApproved

First Approval Date

United States (03 Aug 2000),

Glaucoma, Open-AngleOcular Hypertension

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC25H44O5

InChIKeyXXUPXHKCPIKWLR-JHUOEJJVSA-N

CAS Registry120373-24-2

This study is a multicenter trial performed in Japan, consisting of a comparative study period and a continuous administration period.
Effect of 0.15% UF-021 eye drops on improvement in central retinal sensitivity with HFA will be verified in 52 weeks comparative study period by a placebo-controlled, double-masked study in patients with retinitis pigmentosa.
The safety of same eye drops will also be examined in 52 weeks continuous administration period, in all the patients who completed the comparative study period.

Start Date01 Mar 2013

Sponsor / Collaborator

R-Tech Ueno, Ltd.

100 Clinical Results associated with Unoprostone Isopropyl

Login to view more data

100 Translational Medicine associated with Unoprostone Isopropyl

Login to view more data

100 Patents (Medical) associated with Unoprostone Isopropyl

Login to view more data

266

Literatures (Medical) associated with Unoprostone Isopropyl

01 Jan 2025·Clinical & Experimental Ophthalmology

Comparative analysis of medical treatments for long‐term control of normal tension glaucoma: A systematic review and model‐based network meta‐analysis

Review

Author: Chen, Chun‐Yi ; Lin, Chun‐Ju ; Yang, Ting‐Kai ; Ju, Yuh‐Jen ; Kuo, Hou‐Ting ; Lee, Chien‐Chang ; Chen, Wen‐Hsien ; Wu, Albert Y. ; Ho, Jennifer Hui‐Chun

AbstractBackgroundTo evaluate and compare the long‐term efficacy of medical treatments for normal tension glaucoma (NTG) in controlling intraocular pressure (IOP), and establish a hierarchical ranking based on their effectiveness. ‘Long‐term’ is defined as a treatment duration of over 12 weeks in randomised controlled trials (RCTs).MethodsThis systematic review and model‐based network meta‐analysis (MBNMA) collected data of 795 patients with 997 eyes from RCTs. Patients with NTG were selected based on strict inclusion/exclusion criteria, with randomsation procedures and masking as reported in the individual trials. Eight different medications were compared, including prostaglandin analogues, beta‐blockers, brimonidine, unoprostone isopropyl, brovincamine, and palmitoylethanolamide (PEA). Notably, PEA is an oral medication, while other drugs are topical agents.ResultsPrimary outcome is the long‐term efficacy of IOP control across medications with different follow‐up durations. Among the eight medications, PEA demonstrates the highest efficacy (Surface under the cumulative ranking, SUCRA = 7.46%), followed by two prostaglandin analogues: travoprost (SUCRA = 6.86%) and latanoprost (SUCRA = 6.76%), then two beta‐blockers: nipradilol (SUCRA = 4.90%) and timolol (SUCRA = 4.89%). Both brimonidine and unoprostone isopropyl have SUCRA scores below 4.0%, indicating modest but limited efficacy. Brovincamine has the lowest SUCRA score (1.32%), reflecting minimal effectiveness.ConclusionsThis study revealed PEA as a promising agent for long‐term IOP control in NTG patients, suggesting potential use as primary or adjunctive therapy. The outcomes call for PEA's consideration in clinical practice and highlight the need for further research into its long‐term efficacy and safety for NTG.

01 May 2022·Australasian Journal of DermatologyQ4 · MEDICINE

Topical ophthalmic beta‐blockers are associated with ocular pseudopemphigoid: A pharmacovigilance study of antiglaucoma medications utilising the FDA adverse event reporting system

Q4 · MEDICINE

Article

Author: Jedlowski, Mahdieh Fazel ; Jedlowski, Patrick Michael

ABSTRACTBackground/objectiveThe association between antiglaucoma medications and the development of ocular pseudopemphigoid (OPP) has been described; however, the independent risk of each medication has not been quantified.MethodsCase/non‐case analyses were performed in the FDA Adverse Events Reporting System (FAERS) using data from 2010–2020 to examine the reporting odds ratio (ROR) signal for OPP for all classes of antiglaucoma medications under multiple conditions: (i) comparison to all other drugs in FAERs, (ii) comparison to other antiglaucoma medications, (iii) comparison to vehicle/hydrating eye drops with cases of OPP and (iv) comparison to vehicle/hydrating eyedrops with and without cases of OPP to control for topical irritant and preservative effects.ResultsA statistically significant ROR for OPP was found for aggregate antiglaucoma medications under the first condition but not the third or fourth (i.96.97 (95% CI 52.54–178.98). The largest signal for OPP when compared to other glaucoma drugs and eye drops was seen with unoprostone (ii.68.96 (95% CI 8.35–569.50, iii.39.85 (95% CI 4.14–383.33), iv.581.67 (95% CI 49.38–6851.57) followed by carteolol (ii.32.51(95% CI 9.02–117.67), iii.10.67 (95% CI 1.77–64.13), iv.77.84 (95% CI 12.95–467.78) and betaxolol (ii.23.38 (95% CI 7.28–74.46), iii.6.94 (95% CI 1.27–38.01), iv.50.67 (95% CI 9.26–277.25). A statistically significant ROR was noted only for the beta‐blockers class aggregate under conditions ii and iv.ConclusionsOur findings support an association between OPP and antiglaucoma medications; under the most stringent control for topical irritant/preservative effect by of comparison to topical eye drops, unoprostone, carteolol, betaxolol and timolol all had a significant ROR for OPP.

01 May 2022·British Journal of OphthalmologyQ2 · MEDICINE

Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis

Q2 · MEDICINE

Review

Author: Cui, Amy Xianying ; Barbeau, Martin ; Beauchemin, Catherine ; Royer, Catherine ; Harasymowycz, Paul ; Lachaine, Jean ; Mathurin, Karine ; Jobin-Gervais, Katherine

Background/aimsTo assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP).MethodsA systematic literature review adapted from the Li et al (Ophthalmology, 2016) study was conducted. Medline, Embase and PubMed were searched for randomised controlled trials published between 1 January 2014 and 19 March 2020. Studies had to report IOP reduction after 3 months for at least two different treatments among placebo, PGAs (bimatoprost 0.01%, bimatoprost 0.03%, latanoprost, LBN, tafluprost, unoprostone) or apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide, levobunolol, timolol, travoprost. A Bayesian network meta-analysis was performed to provide the relative effect in terms of mean difference (95% credible interval) of IOP reduction and ranking probabilities. Surface under the cumulative ranking curve (SUCRA) was generated.ResultsA total of 106 trials were included with data for 18 523 participants. LBN was significantly more effective than unoprostone (−3.45 (−4.77 to −2.12)). Although relative effect was not significative, compared with other PGAs, LBN numerically outperformed latanoprost (−0.70 (−1.83 to 0.43)) and tafluoprost (−0.41 (−1.87 to 1.07)), was similar to bimatoprost 0.01% (-0.02(−1.59 to 1.55)) and was slightly disadvantaged by bimatoprost 0.03% (−0.17 (−1.42 to 1.07)). LBN was significantly more efficient than the beta-blockers apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide and timolol. According to SUCRA, LBN was ranked second after bimatoprost 0.03%, followed by bimatoprost 0.01%.ConclusionLBN was significantly more effective than the PGA unoprostone and most of the beta-blockers. Compared with the most widely used PGAs, LBN numerically outperformed latanoprost and travoprost and was similar to bimatoprost 0.01%.

100 Deals associated with Unoprostone Isopropyl

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01452	Unoprostone Isopropyl	S01EE02	DB06826

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	Japan	Nitto Pharmaceutical Industries Ltd.	22 Mar 2007
Ocular Hypertension	Japan	Nitto Pharmaceutical Industries Ltd.	22 Mar 2007

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Retinitis Pigmentosa	Phase 1	Japan	R-Tech Ueno, Ltd.	01 Mar 2013
dry age-related macular degeneration	Discovery	Austria	Sucampo Pharma Americas LLC	01 May 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2014	Not Applicable	Ocular Hypertension \| Glaucoma, Open-Angle	10	Unoprostone isopropyl 0.15% ophthalmic solution	(wyjyinaugf) = cnuvnablzm efveblvyvl (ubvkrrertu, 1.0)	-	01 Apr 2014
JPRN-UMIN000005514 (ARVO2012)	Not Applicable	Retinitis Pigmentosa	22	High dose UF-021	skwovovvvr(yawhgtgibd) = tixiggqzfu wjghmfshgo (aaabuellxe ) View more	-	01 Mar 2012
				Low dose UF-021	skwovovvvr(yawhgtgibd) = qlnslaakbp wjghmfshgo (aaabuellxe ) View more
ARVO2009	Not Applicable	Retinitis Pigmentosa	-	Isopropyl Unoprostone (Group A (Improved retinal sensitivity))	(ilhrcicoqt) = jnshpnftjc akkoencoop (icsmcqembx ) View more	-	01 Apr 2009
				Isopropyl Unoprostone (Group B (No improvement in retinal sensitivity))	(ilhrcicoqt) = ysppuwylbd akkoencoop (icsmcqembx )
ARVO2008	Not Applicable	matrix metalloproteinases (MMPs) \| tissue inhibitors of metalloproteinases (TIMPs)	13	Latanoprost	(vwpdaymkjq) = hgapapuixy egfcxvhevn (pbcxquwxtn, 7) View more	Positive	01 May 2008
				Bimatoprost	jpdcfmsdqk(yfgavnetrn) = dmkejskdef jyrygsipix (twntdwdqad, 34) View more
ARVO2007	Not Applicable	-	-	Latanoprost 30 ng/mL	(cfyhlrdsxh) = zjqfqiqmhe yexftggjrm (licfwtkeie ) View more	-	01 May 2007
				Unoprostone 145 ng/mL	kxoppnhxnr(iuxbxvoqwd) = omwdjeitri voenraddyi (kswsbcyray ) View more
ARVO2004	Not Applicable	-	-	Travoprost acid	jqtywwvcgp(miyssqfhct) = dkkjnkvffw xdzwjooxvp (ohnqrhrkza ) View more	-	01 May 2004
				Bimatoprost acid	jqtywwvcgp(miyssqfhct) = lluqbablzx xdzwjooxvp (ohnqrhrkza ) View more
ARVO2003	Not Applicable	Diabetes Mellitus HbA1c \| ET-1 plasma level	19	Unoprostone isopropyl ophthalmic solution	mtvuevewie(qsxplczbkm) = duwrhdzprt tyjokmnxan (wwofikkshy ) View more	Positive	01 May 2003
ARVO2003	Not Applicable	Ocular Hypertension	-	Unoprostone 0.15%	(dozcmfaixz) = qjwzqetgyk ousemicofw (tmtmrwdkvi ) View more	Positive	01 May 2003
				Vehicle	(dozcmfaixz) = opccbkphjk ousemicofw (tmtmrwdkvi ) View more
ARVO2002	Not Applicable	Ocular Hypertension	161	Latanoprost 0.005%	(lazwsrpgrk) = dleqiupret anjjxlgqmj (bennttuzdb, + 3.9)	Positive	01 Dec 2002
				Unoprostone 0.15%	(lazwsrpgrk) = fidbnciuex anjjxlgqmj (bennttuzdb, + 2.6)
ARVO2002	Not Applicable	Glaucoma, Open-Angle	25	Latanoprost 0.005%	pieolatuac(klqbrfgmtb) = zkugktujju tgfyxqublc (xifedtfipj )	Positive	01 Dec 2002
				Unoprostone 0.15%	pieolatuac(klqbrfgmtb) = oarczodtdt tgfyxqublc (xifedtfipj )